Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-α

European Journal of Clinical Investigation

Volumn 30, Issue 2, 2000, Pages 111-121

  Konrad, Thomas ^a   Zeuzem, S ^a   Vicini, P ^b   Toffolo, G ^c   Briem, D ^a   Lormann, J ^a   Herrmann, G ^a   Berger, A ^a   Kusterer, K ^a   Teuber, G ^a   Cobelli, C ^c   Usadel, K H ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF WASHINGTON   (United States)

^c University of Washington ^*

Author keywords

Glucose tolerance; Hepatitis C; Insulin secretion; Insulin sensitivity; Interferon

Indexed keywords

GLUCOSE; INSULIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON;

ARTICLE; CLINICAL ARTICLE; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEPATITIS C; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIVER BIOPSY; LIVER FIBROSIS; MALE; PRIORITY JOURNAL;

BLOOD GLUCOSE; DIABETES MELLITUS; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HEPATITIS C, CHRONIC; HOMEOSTASIS; HUMANS; INSULIN; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; REGRESSION ANALYSIS;

EID: 0033950690     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2000.00608.x     Document Type: Article

References (56)

1. 1 Petrides AS. Liver disease and diabetes mellitus. Diabetes Rev, 1994;2:2-18.
2. 2 Müller MJ, Willmann O, Rieger A, Fenk A, Selberg O, Lautz HU et al. Mechanism of insulin resistance associated with liver cirrhosis. Gastroenterology, 1992;102:2033-41.
3. 3 Gray H, Wreghitt T, Alexander GJM, Turner RC, O'Rahilly S. High prevalence of hepatitis C infection in afro-caribbean patients with type 2 diabetes and abnormal liver function tests. Diabetic Med, 1995;12:244-9.
4. 4 Özylikan E, Arslan M. Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Am J Gastroenterol, 1997;91:1480-1.
5. 5 Mason AL, Lau JYN, Hoang N, Qian K, Alexander GJM, Xu L et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology, 1999;29:328-33.
6. 6 Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol, 1998;26:30-3.
7. 7 Fraser GM, Harman I, Meller N, Niv Y, Porath A. Diabetes mellitus is associated with chronic hepatitis C but not with chronic hepatitis B infection. 1sr J Med Sci, 1996;32:526-30.
8. 8 Allison MED, Wreghitt T, Palmer CR, Alexander GJM. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol, 1994;21:1135-9.
9. 9 Simó R, Hernández C, Genescà J, Jardì R, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care, 1996;19:998-1000.
10. 10 Brillanti S, Foli M, Gaiani S, Masci G, Miglioli M, Barbara L. Persistent hepatitis C viraemia without liver disease. Lancet, 1993;341:464-5.
11. 11 Tong MJ, Rajender RK, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepatology, 1997;26:747-54.
12. 12 Fabris P, De Floreani A, Lazzari F, Betterle C, Naccarato R, Chiaramonte M. Development of type 1 diabetes mellitus during interferon alpha therapy for chronic HCV hepatitis. Lancet, 1992;340:548.
13. 13 Lopes EPA, Oliveira PM, Ferraz ML, Costa Chrm Miranda W, Miranda W et al. Exacerbation of type 2 diabetes mellitus during interferon-alfa therapy for chronic hepatitis B. Lancet, 1994;343:244.
14. 14 Guerci A-P, Guerci B, Levy-Marchal C, Ongagna J, Ziegler O, Candiloros H et al. Onset of insulin-dependent diabetes mellitus after hairy cell leukaemia. Lancet, 1994;343:1167-8.
15. 15 Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes, 1989;38:641-7.
16. 16 Corssmit EPM, Heijligenberg R, Endert E, Ackermas MT, Sauerwein HP, Romijn JA. Endocrine and metabolic effects of interferon-a in humans. J Clin Endocrinol Metab, 1996;81:3265-9.
17. 17 Kolacynski JW, Taskinen M-R, Hilden H, Kiviluoto T, Cantell K, Koivisto VA. Effects of interferon alpha on insulin binding and glucose transport in human adipocytes. Eur J Clin Invest, 1992;22:292-9.
18. 18 Imano E, Kanda T, Ishigami Y, Kubota M, Ikeda M, Matsuhisa M et al. Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol, 1998;28:189-93.
19. 19 Tanaka H, Shiota G, Kawasaki H. Interferon-alpha therapy alters glucose metabolism in patients with chronic hepatitis B. J Med, 1997;28:325-34.
20. 20 Tanaka H, Shiota G, Kawasaki H. Changes of glucose tolerance after interferon-alpha therapy in patients with chronic hepatitis C. J Med, 1997;28:335-46.
21. 21 Ahrén B. Interferon alpha in the treatment of neuroendocrine tumours: effect on glucose tolerance and glucose-stimulated insulin secretion. Eur J Surg, 1993;159:209-12.
22. 22 Bergman RN, Ider ZY, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol, 1979;236:E667-77.
23. 23 Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man. J Clin Invest, 1981;68:1456-67.
24. 24 Toffolo G, De Grandi F, Cobelli C. Estimation of β-cell sensitivity from intravenous glucose tolerance test C-peptide data. Diabetes, 1995;44:845-54.
25. 25 Dietrich CF, Lee J-H, Herrmann G, Teuber G, Roth KW, Caspary WF et al. Enlargement of perihepatic lymph nodes in relation to liver histology and viremia in patients with chronic hepatitis C. Hepatology, 1997;26:467-72.
26. 26 Preston H, Wright TL. Interferon therapy for hepatitis C. Lancet, 1995;348:973-4.
27. 27 Zeuzem S, Schmidt JM, Lee J-H, Rüster B, Roth K. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology, 1996;23:366-71.
28. 28 Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R et al. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med, 1982;96:549-56.
29. 29 Tilg H, Vogel W, Dinarello CA. Interferon-α induces circulating tumor necrosis factor receptor p55 in humans. Blood, 1995;2:433-5.
30. 30 Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O et al. The long-term pathological evolution of chronic hepatitis C. Hepatology, 1996;23:1334-40.
31. 31 Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N et al. Formation and application of a numerical scoring system for assessing histologic activity in asymptomatic chronic active hepatitis. Hepatology, 1981;1:431-5.
32. 32 Konrad T, Vicini P, Kusterer K, Höflich A, Assadkhani A, Böhles HJ et al. α-lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care, 1999;22:280-7.
33. 33 The validation of models of metabolic and endocrine systems. In: Carson RE, Cobelli C, Finkelstein L, editors. The Mathematical Modeling of Metabolic and Endocrine Systems. Vancouver:John Wiley & Sons;1983.p.217-368.
34. 34 National diabetes data group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes, 1979;28:1039-57.
35. 35 Cerasi E, Luft R. The plasma insulin response to glucose infusion in healthy subjects and in diabetes mellitus. Acta Endocrinol, 1967;55:278-304.
36. 36 The METAVIR cooperative group. Inter-and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology, 1994;20:15-20.
37. 37 Kruszynska YT, Harry DS, Bergman RN, Mcintyre N. Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and non-diabetic cirrhotic patients. Diabetologia, 1993;36:121-8.
38. 38 Letiexhe MR, Scheen AJ, Gerard PL, Bastens BH, Pirotte J, Belaiche J et al. Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients. J Clin Endocrinol Metab, 1993;77:1263-8.
39. 39 Marchesini G, Pacini G, Bianchi G, Patrono D, Cobelli C. Glucose Disposal, β-cell secretion, and hepatic insulin extraction in cirrhosis: a minimal model assessment. Gastroenterology, 1990;99:1715-22.
40. 40 Rayfield EJ, Curnow RT, George DT, Beisel WR. Impaired carbohydrate metabolism during mild viral illness. N Engl J Med, 1973;289:618-21.
41. 41 Petrides AS, Stanley T, Matthews DE, Vogt C, Bush AJ, Lambeth H. Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology, 1998;28:141-9.
42. 42 Wong VS, Wight DGD, Palmer RC, Alexander GJM. Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model. J Clin Pathol, 1996;49:465-9.
43. 43 Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta, 1997;261:159-65.
44. 44 Gurakar A, Fagiuoli S, Faruki H, De Maria N, Balkan M, Van Thiel DH et al. Utility of hepatitis C virus RNA determination in hepatic tissue as an end point for interferon treatment of chronic hepatitis C. Hepatology, 1995;22: 1109-12.
45. 45 Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology, 1992;15:567 71.
46. 46 Niederau C, Berger M, Stremmel W, Starke A, Strohmeyer G, Ebert R et al. Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation? Diabetologia, 1984;26:441-4.
47. 47 Mccullough AJ, Tavill AS. Disordered energy and protein metabolism in liver disease. Semin Liver Dis, 1991;11:265-77.
48. 48 Magnusson J, Tranberg K-G. Impaired early response to intravenous glucose in alcoholic liver cirrhosis. Scand J Gastroenterol, 1987;22:301-7.
49. 49 Grimbert S, Valensi P, Levy-Marchal C, Perret G, Richardet JP, Raffoux C et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol, 1996;20:544-8.
50. 50 Shinohara E, Yamashita S, Kihara S, Hirano K-I, Ishigami M, Arai T et al. Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipoases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology, 1997;25:1502-6.
51. 51 Jacob S, Perrillo RP, Zimmermann R, Mason AL. Improved glucose metabolism after α-interferon therapy in patients with chronic hepatitis C. Hepatology, 1997;26:304A.
52. 52 Cobelli C, Pacini G. Insulin secretion and hepatic extraction in humans by minimal modeling of C-peptide and insulin kinetics. Diabetes, 1988;37:223-31.
53. 53 Piatti PM, Monti LD, Davis SN, Conti M, Brown MD, Pozza G et al. Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM. Diabetologia, 1996;39:103-12.
54. 54 Randle PJ, Hales CN, Garland PB, Newsholme EA. The glucose-fatty-acid cycle. Lancet, 1963;i:785-9.
55. 55 Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med, 1999;341:240-6.
56. 56 Del Rey A, Besedovsky H. Antidiabetic effects of interleukin 1. Proc Natl Acad Sci, 1989;86:5943-7.